| EPB148 | Advanced HIV infection in the US: immune response to ART initiation | E-poster | ART in acute, first- and second-line therapies |
| EPB149 | Higher CD4/CD8 ratio recovery observed among people living with HIV started with integrase strand transfer inhibitors | E-poster | ART in acute, first- and second-line therapies |
| EPB150 | Long-term integrated analysis of B/F/TAF in treatment-naïve adults with HIV through five years of follow-up | E-poster | ART in acute, first- and second-line therapies |
| EPB151 | A pilot study of the impact of a rapid ART initiation in advanced HIV disease | E-poster | ART in acute, first- and second-line therapies |
| EPB152 | Country of birth influences INSTI prescription in treatment-naive patients living with HIV in France | E-poster | ART in acute, first- and second-line therapies |
| EPB153 | Starting antiretroviral therapy (ART) at the first HIV-specialist appointment with or without baseline laboratory data with BIC/FTC/TAF (The BIFAST study) | E-poster | ART in acute, first- and second-line therapies |
| OAB0302 | Efficacy and safety of dolutegravir plusemtricitabinevs combined antiretroviral therapy for the maintenance of viral suppression: 144-week results of the SIMPL'HIV trial | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0303 | Dual therapy based on DRVr plus 3TC in HIV-1 naïve patients: global 48 week results from ANDES Study | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0304 | Dolutegravir versus efavirenz-400 as first-line ART in Cameroon: week 192 data of NAMSAL trial | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |
| OAB0305 | Survival in advanced AIDS patients treated with efavirenz or dolutegravir in Brazil: a multicenter, observational study | Oral abstract session with live Q&A | ART in acute, first- and second-line therapies |